Janux Therapeutics, Inc.
JANX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 13.76 | 0.62 | -0.09 | -0.06 |
| FCF Yield | -1.53% | -11.10% | -9.04% | -2.27% |
| EV / EBITDA | -25.52 | -6.72 | -7.85 | -23.72 |
| Quality | ||||
| ROIC | -9.45% | -19.78% | -19.26% | -8.93% |
| Gross Margin | 80.54% | 75.81% | 90.23% | 96.89% |
| Cash Conversion Ratio | 0.64 | 0.87 | 0.68 | 0.52 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.13% | 30.50% | – | – |
| Free Cash Flow Growth | 15.74% | -6.19% | -167.46% | -322.48% |
| Safety | ||||
| Net Debt / EBITDA | 4.21 | -0.08 | 0.39 | 1.08 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -1.20 | -0.57 |
| Cash Conversion Cycle | -527.85 | -354.98 | -1,211.16 | -8,565.50 |